01.19.23 -- How CVS, Walgreens, & Walmart Will Transform Trial Recruitment

A new development could potentially change the patient recruitment challenge. In 2022, CVS, Walgreens, and Walmart officially entered the clinical trials space. The patient access capabilities of all three organizations may change the way drug developers access patients while also solving the patient diversity problem.

Delve into the understanding of how smaller biotech companies should approach CRO selection and what they should consider before launching their clinical development program.

KPS Life brings "A" team resources that are 100% dedicated to sponsors and create a collaborative, supportive process where a complete control of operations is maintained.

Picture this: The FDA accepts a manufacturer's NDA, and the manufacturer plans for its impending launch. But shortly before the anticipated approval, the FDA notifies the manufacturer that a risk evaluation and mitigation strategy (REMS) program is required to market the product. Now what?

In this white paper, learn why western biopharma companies should take advantage of China’s revamped regulatory framework.

Manufacturers with aging facilities and technologies are certainly in danger of being found by inspectors to not meet the requirement to remain “current” under cGMPs.

The $118 billion combination-product market is projected to increase at a CAGR of 8.8%. This article answers the question: “Is this actually a combination product? What do we need to do if it is?”

Understand Clinical Trials Regulation No. 536/201 (CTR) labeling changes and their potential to disrupt traditional clinical supply strategies should sponsors misunderstand or fail to adhere to the new requirements.

Our regulatory consultants take action and move your research forward. If you’re looking for help in the development of innovative life sciences and digital health products, then Advarra is the answer.

Support your local safety needs and drive consistency with global requirements through end-to-end solutions with regulatory-focused medical experts and leading technologies.